Trinity Life Sciences buys CBPartners

Trinity Life Sciences, a Boston-based life sciences consultancy, has acquired CBPartners, a New York-based boutique life sciences strategy consulting firm.

Founded in 2012, CBPartners advises private and public sector health and life sciences clients on value, access, and pricing; commercial strategic planning; and government policy advisory. The firm advises on maximizing access and pricing opportunity across all phases of development, creating tailored product and portfolio strategies to optimize value, and developing evidence-based policies that aim for an increased standard of care, affordability, and equity.

CBPartners has worked with large pharmaceutical and biopharmaceutical firms, as well as ministries of health in emerging markets. The consultancy has over 75 professionals across offices in New York, San Francisco, and London.

“Pricing and access issues have been the Achilles’ heel of many recent drug launches,” said David Fitzhenry, CEO of Trinity Life Sciences. “With the addition of CBPartners, Trinity is better poised to help our clients revolutionize the commercial model and provide their drugs to patients around the world. The addition of CBPartners will also broaden our work in emerging markets allowing us to assist our clients on a more global scale.”The acquisition will bolster Trinity’s value, pricing, and access business and expand its offices in New York, San Francisco, and London. The firm has more than 1,600 employees across nine offices in the US, Canada, UK, Germany, and India.

“CBPartners’ focus on global pharmaceutical pricing and market access issues will be enhanced by Trinity’s commercial strategy heritage and real-world data,” said Mónica Martín de Bustamante, CEO & managing director of CBPartners. “We are excited to offer the additional services in the Trinity portfolio – commercial strategy, launch planning, market research, forecasting, benchmarking, etc. – to our client base so we can develop stronger cross-functional strategies that demonstrate a product’s value. It is exciting to be part of the Trinity team.”

Trinity has been serving life sciences clients for more than 20 years with services in advisory, insights and analytics, and technology. Its advisory offerings include corporate strategy, product planning and forecasting, portfolio strategy, and business development support. Trinity also offers an array of market intelligence, research, and benchmarking services, as well as proprietary technology products for data and analytics.

The deal arrives shortly after Oliver Wyman added a similar number of consultants in its acquisition of Huron's life sciences strategy business.